GlassScriptPhysician profile
Erika L Sheng
NPI 1225863020
$5,130.07
in general payments reported to CMS, 2019-2025
22 companies · $3,993 in 2025
The $3,993 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,137 · 2025: $3,993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,932 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,931.73 |
| Education | $198.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $834.06 | 2025 | Dupixent, Libtayo |
| Genzyme Corporation | $500.26 | 2025 | |
| Arcutis Biotherapeutics, INC. | $492.36 | 2024-2025 | Zoryve |
| Galderma Laboratories, L.P. | $439.67 | 2024-2025 | Nemluvio, Aklief |
| Abbvie INC. | $328.64 | 2024-2025 | |
| Lilly USA, LLC | $321.78 | 2024-2025 | Ebglyss, Taltz |
| Novartis Pharmaceuticals Corporation | $321.11 | 2024-2025 | |
| Leo Pharma INC. | $280.84 | 2024-2025 | Adbry, Anzupgo, Spevigo |
| Janssen Biotech, INC. | $209.84 | 2025 | Tremfya |
| Incyte Corporation | $204.83 | 2024-2025 | Opzelura |
| Organon LLC | $173.36 | 2025 | Vtama |
| Ucb, INC. | $160.26 | 2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $132.96 | 2025 | |
| Dermavant Sciences, INC. | $116.57 | 2024 | Vtama |
| Pfizer INC. | $115.72 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $105.53 | 2024 | Cabtreo |
| Almirall LLC | $96.72 | 2024-2025 | Seysara |
| Amgen INC. | $93.74 | 2024-2025 | Otezla, Otezla |
| Ani Pharmaceuticals, INC. | $76.38 | 2025 | Sovuna |
| E.R. Squibb & Sons, L.L.C. | $68.92 | 2025 | Sotyktu |
| Mayne Pharma Commercial LLC | $32.06 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.46 | 2025 | Spevigo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erika Sheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.